Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1886248 | 1.00 | HCAR2 (0.51) | HCAR2CA12CA1CA2CA7 | |
| Trifluoroacetic Acid SCHEMBL1580121 | 0.92 | HCAR2 (0.44) | HCAR2CA12CA1CA2CA7 | |
| Trifluoroacetic Acid SCHEMBL1580120 | 0.92 | HCAR2 (0.44) | HCAR2CA12CA1CA2CA7 | |
| SCHEMBL2302954 | 0.86 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2302950 | 0.86 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1580130 | 0.84 | LMNA (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL25110900 | 0.84 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1511286 | 0.84 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30805888 | 0.84 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1511284 | 0.84 | CA12 (0.48) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310364-B1 | HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS | DAC SRL (IT) | 2013-01-02 | — | — | EP | disclosed |
| US-20110105474-A1 | HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS | DAC S.R.L. | 2011-05-05 | — | — | US | disclosed |
| EP-2133334-A1 | Heterocyclic derivatives as HDAC inhibitors | DAC S.r.l. (IT) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105474-A1 | HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS | HDAC3, HDAC1, HDAC5 | HCAR2 503/4885CA12 1983/4885CA1 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.